Edesa Biotech, INC Schedule 13G passive stakes

Several entities affiliated with Millennium Management have reported a combined beneficial ownership of 5.4% of Edesa Biotech's common shares.

Stonepine Capital Management has filed a Schedule 13G reporting a 0.3% beneficial ownership stake in Edesa Biotech, Inc.

Nantahala Capital Management and its principals have filed an amendment indicating they no longer hold any beneficial ownership in Edesa Biotech.

Point72 Asset Management, L.P. and Steven A. Cohen disclose a beneficial ownership of 2 common shares in Edesa Biotech, Inc.

Rubric Capital Management LP and David Rosen have reported a 7.74% beneficial ownership stake in Edesa Biotech, Inc. via a Schedule 13G filing.

Sirenia Capital Management LP and Alex Silverstein jointly report a 7.2% stake in Edesa Biotech, Inc. as of March 31, 2026.

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a 6.7% beneficial ownership stake in Edesa Biotech, Inc.

Point72 Asset Management, along with Point72 Capital Advisors and Steven A. Cohen, has reported a 7.2% beneficial ownership stake in Edesa Biotech, Inc.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed a 9.99% beneficial ownership stake in Edesa Biotech, Inc.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 9.99% in EDESA BIOTECH, INC. common shares.

Stonepine Capital Management, LLC and its affiliates have filed a Schedule 13G, reporting a 9.9% beneficial ownership stake in Edesa Biotech, Inc.'s common stock.

Thomas A. Satterfield, Jr. has filed an amended Schedule 13G indicating zero beneficial ownership of Edesa Biotech, Inc. common stock, primarily due to recent share issuances by the company.

Thomas A. Satterfield, Jr. has filed an amended Schedule 13G, reporting a 6.7% beneficial ownership stake in Edesa Biotech, Inc. as of December 31, 2024.